Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.
about
M-Cells Contribute to the Entry of an Oral Vaccine but Are Not Essential for the Subsequent Induction of Protective Immunity against Francisella tularensisLive attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primatesIntranasal immunization with an archaeal lipid mucosal vaccine adjuvant and delivery formulation protects against a respiratory pathogen challengeMonophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.The Fischer 344 rat reflects human susceptibility to francisella pulmonary challenge and provides a new platform for virulence and protection studiesFrancisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice.Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112ΔiglB::fljB.Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs.Tularemia vaccines: recent developments and remaining hurdles.Mucosal immunization with live attenuated Francisella novicida U112ΔiglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat modelA mucosal subunit vaccine protects against lethal respiratory infection with Francisella tularensis LVS.Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strainsMast cell TLR2 signaling is crucial for effective killing of Francisella tularensis.Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ΔfopC vaccine strain.Infection of mice with Francisella as an immunological modelFrancisella DnaK inhibits tissue-nonspecific alkaline phosphatase.Increased susceptibility of IgA-deficient mice to pulmonary Francisella tularensis live vaccine strain infectionVaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strains.Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge.Novel vaccine approaches for protection against intracellular pathogens.Uncovering the components of the Francisella tularensis virulence stealth strategyImproving T cell-induced response to subunit vaccines: opportunities for a proteomic systems approach.Respiratory and oral vaccination improves protection conferred by the live vaccine strain against pneumonic tularemia in the rabbit model.Development of a novel Francisella tularensis Live Vaccine Strain expressing ovalbumin provides insight into antigen-specific CD8+ T cell responses.Comparison of gene expression in post-smolt Atlantic salmon challenged by LF-89-like and EM-90-like Piscirickettsia salmonis isolates reveals differences in the immune response associated with pathogenicity.Sublingual vaccination with sonicated Salmonella proteins and mucosal adjuvant induces mucosal and systemic immunity and protects mice from lethal enteritis.
P2860
Q27314549-B585F296-0A95-450A-AC8C-E2C22D206536Q27323387-3E2375A6-2D52-472F-8C45-541887C0A4D7Q28743895-C353DCA9-A60A-4D33-9304-CB3AFAD82C19Q30275022-DF4FA3D4-9859-4259-B7B5-341B068F03BCQ33550808-456AA9BF-2EEC-4241-B4BE-61EEAC2D7CC5Q33627084-FD85445B-8F8A-49B9-8E07-124D96710AAFQ33653480-0F0C9CA4-D5FB-4D80-98E4-3CC37E3C7669Q34074366-BF755D73-D040-4080-8D65-825EF4174EA8Q34126301-1CF92FC7-8140-48C9-94C0-EB6F0C45FB4EQ34180914-5AF439E4-58E8-41EA-9CFA-95349E7E2174Q34464553-78436E94-88C3-4E13-94BE-4F77DA1D482BQ34500312-FE1D048E-BB1A-4A7B-98D4-72243FA43F4EQ34740339-ECE4BDE4-8827-4400-A35F-386A7893293FQ35980874-38F2CB40-5B7C-4858-AD4C-18D8F9D622A0Q36018212-9D4C9B6C-9C96-4B44-9EC9-AFC5998C78ABQ36119858-97241B2D-82EA-458E-9D27-616ED2C23D6AQ36347784-344BE793-34B6-484B-9401-BB808FB8BC48Q37123754-A366EB4B-60CF-4D11-9279-B1047D582D3CQ37319753-6DA578D7-A8B5-4B18-A69D-62AFC15B1345Q37364640-C97C26DE-C04A-4FB4-928C-8A492B285FBDQ38194389-7BAC3519-2292-4830-B949-E9022228F98AQ38196816-84781149-139E-4F4C-A8E1-94C543931DECQ38364597-6B59BB48-4424-4160-8105-1735266E3206Q40093204-826EAC35-1B2D-4E1D-929B-FD321762BCC7Q47239165-BD796AD8-5F1D-4195-9A54-F91EF4945587Q47809204-D413F7E9-04E9-459D-8F76-A5F751C6BA61Q50041664-802B6D14-63F6-483E-8664-4E97CF48F425
P2860
Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oral live vaccine strain-induc ...... s, including immunoglobulin A.
@en
Oral live vaccine strain-induc ...... s, including immunoglobulin A.
@nl
type
label
Oral live vaccine strain-induc ...... s, including immunoglobulin A.
@en
Oral live vaccine strain-induc ...... s, including immunoglobulin A.
@nl
prefLabel
Oral live vaccine strain-induc ...... s, including immunoglobulin A.
@en
Oral live vaccine strain-induc ...... s, including immunoglobulin A.
@nl
P2093
P2860
P356
P1476
Oral live vaccine strain-induc ...... s, including immunoglobulin A.
@en
P2093
Ashlesh K Murthy
Bernard P Arulanandam
Dale M Selby
Heather J Ray
Jeffrey R Barker
Karl E Klose
M Neal Guentzel
P2860
P304
P356
10.1128/CVI.00405-08
P577
2009-02-11T00:00:00Z